Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Carlyn Tan, Kylee H Maclachlan, David Nemirovsky, Andriy Derkach, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi A Shah, Sridevi Rajeeve, Dhwani Patel, Tala Shekarkhand, Colin Rueda, Oscar Boutros Lahoud, Gunjan L. Shah, Michael Scordo, David Chung, Heather Landau, Sergio A. Giralt, Alexander Lesokhin, Saad Z Usmani, Neha Korde
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389220668